Publications by authors named "F Crowley"
Predicting whether a patient with cancer will benefit from immune checkpoint inhibitors (ICIs) without resorting to advanced genomic or immunologic assays is an important clinical need. To address this, we developed and evaluated SCORPIO, a machine learning system that utilizes routine blood tests (complete blood count and comprehensive metabolic profile) alongside clinical characteristics from 9,745 ICI-treated patients across 21 cancer types. SCORPIO was trained on data from 1,628 patients across 17 cancer types from Memorial Sloan Kettering Cancer Center.
View Article and Find Full Text PDFArticle Synopsis
- Adjuvant mFOLFIRINOX (mFFX) is a standard treatment for patients with resected pancreatic ductal adenocarcinoma (PDAC), but there is limited information on its effectiveness outside of clinical trials.
- A study of 147 patients showed a median recurrence-free survival (RFS) of 26 months, with some patients over 70 years experiencing a median overall survival (OS) of 51 months.
- Starting mFFX treatment within 8 weeks of surgery was linked to better survival outcomes, while certain genetic factors like KRAS mutations suggested poorer RFS and OS.
Article Synopsis
- Researchers studied how immune checkpoint inhibitors (ICIs) used before liver surgery can affect tumor regression in patients with hepatocellular carcinoma and their impact on relapse-free survival.* -
- The analysis involved data from five clinical trials across various countries, focusing on adults with diagnosed liver cancer who had specific health criteria and no previous ICI treatments.* -
- Out of 111 patients, 104 provided data on tumor response, showing that a significant number (78%) experienced substantial tumor regression, with correlations found between tumor response measurements and relapse-free survival rates.*
Purpose: Patients undergoing axillary lymph node dissection (ALND) for breast cancer face a high risk of lymphedema, further increased by high body mass index (BMI) and insulin resistance. GLP-1 receptor agonists (GLP-1RAs) have the potential to reduce these risk factors, but their role in lymphedema has never been investigated. The purpose of this study was to determine if GLP-RAs can reduce the risk of lymphedema in patients undergoing ALND.
View Article and Find Full Text PDF